ICON Public Limited (NASDAQ:ICLR – Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,390,000 shares, a drop of 6.7% from the March 15th total of 1,490,000 shares. Based on an average daily trading volume, of 551,500 shares, the days-to-cover ratio is currently 2.5 days. Currently, 1.7% of the company’s shares are short sold.
Institutional Investors Weigh In On ICON Public
Institutional investors and hedge funds have recently made changes to their positions in the company. Bruce G. Allen Investments LLC acquired a new stake in shares of ICON Public in the 4th quarter valued at $25,000. LM Advisors LLC acquired a new position in ICON Public during the 4th quarter worth about $26,000. Riverview Trust Co acquired a new position in ICON Public during the 1st quarter worth about $31,000. Livelsberger Financial Advisory acquired a new position in ICON Public during the 4th quarter worth about $29,000. Finally, Pinnacle Bancorp Inc. lifted its position in ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after buying an additional 55 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.
ICON Public Stock Performance
ICON Public stock traded down $1.23 on Wednesday, hitting $292.80. The company’s stock had a trading volume of 178,023 shares, compared to its average volume of 540,825. The firm has a market cap of $24.15 billion, a P/E ratio of 39.91, a price-to-earnings-growth ratio of 1.41 and a beta of 1.15. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.40. The company has a fifty day moving average price of $315.94 and a 200-day moving average price of $280.08. ICON Public has a one year low of $181.92 and a one year high of $344.77.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of ICON Public from $295.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Barclays raised their price target on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Evercore ISI raised their price target on shares of ICON Public from $325.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, February 23rd. Truist Financial raised their price target on shares of ICON Public from $357.00 to $367.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Finally, Mizuho restated a “buy” rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, ICON Public has an average rating of “Moderate Buy” and a consensus price target of $319.45.
View Our Latest Report on ICON Public
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
- Five stocks we like better than ICON Public
- Comparing and Trading High PE Ratio Stocks
- United Airlines Soars on Earnings Beat
- Earnings Per Share Calculator: How to Calculate EPS
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Healthcare Dividend Stocks to Buy
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.